Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.39 |
| ▸ | BMP1 | P13497 | 3/20 | 0.37 |
| ▸ | MMP8 | P22894 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324242 | 1.00 | F2 (0.43) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6323799 | 0.84 | AVPR1B (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6324491 | 0.84 | AVPR1B (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6324773 | 0.80 | AVPR1B (0.39) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6323795 | 0.79 | F2 (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6323789 | 0.79 | F2 (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6325244 | 0.78 | AVPR1B (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6324238 | 0.78 | AVPR1B (0.42) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6318039 | 0.78 | AVPR1B (0.43) | F2AVPR1BAVPR1ABMP1MMP8 | |
| SCHEMBL6324767 | 0.75 | BMP1 (0.40) | F2AVPR1BAVPR1ABMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | F2 691/4885AVPR1B 2300/4885AVPR1A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.